截至2025年11月14日收盘，春立医疗（688236）报收于27.48元，较上周的26.62元上涨3.23%。本周， 春立医疗11月12日盘中最高价报28.57元。11月10日盘中最低价报26.38元。春立医疗当前最新总市值 105.4亿元，在医疗器械板块市值排名37/126，在两市A股市值排名1815/5165。 本周关注点 公司公告汇总 H股公告：须于披露的交易 北京市春立正達醫療器械股份有限公司於2025年11月11日訂立三份結構性存款產品協議，分別使用A股 公開發行的臨時閒置募集資金及內部資源認購北京銀行（大興支行）和北京銀行（方莊支行）的結構性 存款產品，總金額為人民幣790百萬元。該等交易構成須予披露交易，獲豁免股東批准。此前於2025年9 月26日認購上海浦東發展銀行結構性存款產品協議已贖回。公司承認先前未及時披露相關交易，並將加 強內部合規管理。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：春立医疗订立总金额为人民币790百万元的结构性存款产品协议。 ...

智通财经APP讯，鲁大师(03601)发布公告，为充分地利用集团闲置资金以获得更好的资金回报，于2025 年11月13日，公司附属公司成都米加游与招商银行订立结构性存款产品协议XLVIII，据此，成都米加游 同意向招商银行认购人民币5000万元的结构性存款产品。认购资金为结构性存款产品协议 XLVII项下之 已赎回本金。 ...

Core Insights - The recent announcement by Inner Mongolia's Tongyu Mengyin Village Bank to cancel its 5-year fixed deposit product marks a significant shift in the banking sector, reflecting a broader trend of declining deposit rates and the market's response to interest rate adjustments [1][3][6] Deposit Rate Trends - Many banks are suspending or lowering the rates on 5-year fixed deposit products, with some banks like China Merchants Bank offering only a 1.3% interest rate for 5-year deposits, which is lower than the 1.4% for 2-year deposits [2][4] - The phenomenon of longer-term deposit rates being lower than shorter-term rates has become common, with several banks reporting that their 5-year deposit rates are less attractive compared to 3-year options [3][5] Market Dynamics - The market for 3-year specialty fixed deposit products is highly competitive, with customers needing to "抢" (grab) limited quotas, indicating a scarcity of available products [1][2] - Banks are adjusting their deposit products in response to market conditions, with some banks increasing the entry thresholds for 3-year deposits, reflecting a shift in customer demand and risk appetite [3][4] Future Outlook - Industry experts predict that deposit rates will continue to decline, driven by banks' need to reduce funding costs and maintain profitability amid shrinking net interest margins [6][7] - The ongoing adjustments in deposit products and rates are seen as necessary for banks to manage their liabilities effectively, especially for smaller banks that may struggle with long-term deposits [8][9]

Core Viewpoint - The company has approved the use of temporarily idle raised funds for cash management, with a total limit not exceeding 150 million yuan, ensuring that it does not affect the implementation of investment projects or the safety of the raised funds [1] Group 1: Cash Management Redemption Situation - On September 30, 2025, the company signed a contract with China Merchants Bank for a structured deposit product using 30 million yuan of temporarily idle raised funds [2] - The cash management product has matured, and the company has completed the redemption process, with both principal and earnings returned to the corresponding raised funds account [3] Group 2: Recent Cash Management Usage - As of the date of this announcement, the company has utilized raised funds for cash management over the past twelve months [4]

Trading Information Summary - On November 11, 2025, the stock of Chunli Medical (688236) closed at 27.09 CNY, down 3.25%, with a turnover rate of 1.02% and a trading volume of 29,400 shares, resulting in a transaction amount of 80.51 million CNY [1][2] - On the same day, the net inflow of main funds was 3.15 million CNY, accounting for 3.91% of the total transaction amount [2] Company Announcement Summary - Chunli Medical entered into three structured deposit agreements on November 11, 2025, using a total of 790 million CNY from temporarily idle funds raised from A-share public offerings and internal resources to subscribe to structured deposit products from Beijing Bank [1][2] - These transactions are classified as disclosable transactions but are exempt from shareholder approval [1][2] - The company acknowledged a prior failure to timely disclose related transactions and will enhance internal compliance management [1]

Core Viewpoint - Spring Medical (01858.HK) has entered into agreements with Beijing Bank for structured deposit products, utilizing temporary idle funds raised from its A-share public offering, totaling RMB 2.9 billion and RMB 2.1 billion for different branches [1] Company Summary - Spring Medical has agreed to invest a total of RMB 2.9 billion in structured deposits with Beijing Bank (Daxing Branch) and RMB 2.1 billion with Beijing Bank (Fangzhuang Branch) [1] - Additionally, the company will use internal resources to invest another RMB 2.9 billion in structured deposits with Beijing Bank (Fangzhuang Branch) [1] - As of November 11, 2025, Spring Medical's stock closed at HKD 19.12, with a slight increase of 0.21% and a trading volume of 860,000 shares, amounting to HKD 16.44 million [1] Industry Summary - Spring Medical's market capitalization is HKD 1.815 billion, ranking 17th in the medical device II industry [1] - Key performance indicators for Spring Medical compared to the industry average are as follows: - ROE: 5.6% vs. -4.03% (ranked 10th) - Market capitalization: HKD 1.815 billion vs. HKD 5.268 billion (ranked 17th) - Revenue: HKD 913 million vs. HKD 1.195 billion (ranked 10th) - Net profit margin: 23.48% vs. -16.5% (ranked 5th) - Gross margin: 67.09% vs. 54.89% (ranked 11th) - Risk rate: 16.62% vs. 29.03% (ranked 65th) [1]

Core Viewpoint - Spring Medical (01858) has entered into multiple structured deposit agreements with Beijing Bank and Shanghai Pudong Development Bank, utilizing temporary idle funds raised from its A-share public offering for investment purposes [1] Group 1: Structured Deposit Agreements - The company has agreed to invest a total of RMB 2.9 billion in a structured deposit product with Beijing Bank (Daxing Branch) using idle funds from its A-share public offering [1] - Additionally, the company will invest RMB 2.1 billion in another structured deposit product with Beijing Bank (Fangzhuang Branch) from the same source [1] - The company has also committed RMB 2.9 billion to a second structured deposit product with Beijing Bank (Fangzhuang Branch) using internal resources [1] Group 2: Other Financial Agreements - On September 26, 2025, the company entered into a structured deposit agreement with Shanghai Pudong Development Bank (Haidian Park Branch), agreeing to invest RMB 85 million using internal resources [1] - The structured deposit agreement with Shanghai Pudong Development Bank (Haidian Park Branch) was redeemed prior to the announcement date [1]

Core Viewpoint - Spring Medical (01858.HK) has announced the establishment of structured deposit agreements with Beijing Bank, utilizing temporarily idle funds raised from its A-share public offering, totaling RMB 7.9 billion [1] Group 1: Structured Deposit Agreements - The company has entered into a structured deposit product agreement with Beijing Bank (Daxing Branch) for a total amount of RMB 290 million [1] - Additionally, a structured deposit product agreement with Beijing Bank (Fangzhuang Branch) has been established for a total amount of RMB 210 million [1] - The company also agreed to use internal resources to subscribe to another structured deposit product with Beijing Bank (Fangzhuang Branch) for a total amount of RMB 290 million [1]

南财智讯11月10日电，万盛股份公告，公司拟在2026年度使用不超过6亿元的闲置自有资金购买期限 短、中低风险、流动性好的理财产品或结构性存款产品。投资期限为2026年度内，单个理财产品期限不 超过12个月。该事项已经公司第五届董事会第二十七次会议审议通过，尚需提交股东会审议。资金来源 为公司闲置自有资金，授权公司董事长在额度和期限范围内行使决策权并签署相关文件，财务部门负责 具体办理。 ...

Core Points - Zhejiang Rongtai announced the redemption of structured deposit products totaling 140 million RMB from Hangzhou Bank and Bank of Communications, resulting in a profit of 444,300 RMB [1] - The company will reinvest 120 million RMB of idle raised funds for cash management, which will not affect the progress of investment projects or normal operations [1]